Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) https://validator.w3.org/feed/docs/rss2.html Our Team Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma. Division of Hematology, Department of Medicine, Faculty of Medicine Thammasat University Stem Cell and Molecular Biology, Center of Excellence in Stem Cell Research and Innovations, Faculty of Medicine, Thammasat University TTCI Showcases Emerging Immuno-Oncology Talent and Invites Global Community to Thailand for WIC-APAC 2027 Basic Cancer Immunology for Clinicians Department of Paediatrics, Faculty of Medicine, Thammasat University Member Contents A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy in glioblastoma models Affordable Immunotherapy: Opportunities and Challenges CAR T-cell Immunometabolism: Insights from Patients Division of Cell Biology, Department of Preclinical Sciences, Faculty of Medicine, Thammasat University AP-SciBio 2027 x WIC APAC 2027 & Thai Immunology Annual Meeting CAR T-cell therapy for paediatric solid tumours: clinical trial development and preclinical modelling TTCI to Participate in WIC-APAC 2026 Thailand Successfully Hosts Its First WIC APAC Webinar, Drawing Strong Regional Interest in Personalized Cancer Vaccines Cell Therapy for Solid Cancers: Promise or Overpromise? Antibody-Drug Conjugates (ADCs): Recent Advances in the Treatment of Solid Tumors Antibody-Drug Conjugates (ADCs) – Recent Advances in the Treatment of Solid Tumors Cell Therapy for Solid Cancers – Promise or Overpromise? Personalized Cancer Vaccines – A New Frontier in Thailand’s Fight Against Cancer TTCI Representative Highlights CAR-T Cell Therapy Roadmap at the 74th JSTMCT Annual Meeting in Yokohama CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML TTCI Researchers Present and Collaborate at the 29th Annual Meeting of the Japanese Association of Cancer Immunology TTCI at a glance Chiang Mai University Team Mahidol University Team NRCT Hosts Seminar on “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment” at MHESI Fair 2025 Thai Immunology Annual Meeting 2026 International Collaborator IPOPI | SEAPID | Chulalongkorn | Erasmus MC Meeting 2026 Pediatric Neuro-Oncology Consortium – Chulalongkorn University Research Forum Scientific Meeting: Medical Applications of Gene Editing and Synthetic Biology Technologies White Paper Government Agencies and Related Announcements IMMUNOLOGY SEMINAR: PEPTIDE CANCER VACCINE EXPERIENCE AT NCI TTCI Webinar “CAR T-cell Immunometabolism, Insights from Patients” Thammasat University Team Chulalongkorn University Team Patient Care and Toxicities Management of CAR T-cell in Pediatrics Affordable Immunotherapy – Opportunities and Challenges Registration Open: 1st International Scientific Symposium in Hematologic Malignancy (CETH, Chulalongkorn University) Khonkaen University Team University of Wisconsin School of Medicine and Public Health A multi-center clinical research project to study the Safety and Efficacy of CD19 CAR T-cells in ALL (Acute Lymphoblastic Leukemia) by Academic Hubs On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy in glioblastoma models